Clinical trials: Hepatitis B, completed
Hepatitis B, Liver Transplantation
Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver
The primary purpose of this study is to evaluate the efficacy of adefovir (ADV) in preventing de novo Hepatitis B in patients who receive Hepatitis B core antibody (HBcAb) positive grafts but who are not Hepatitis B Surface…
- Trial name
- NCT01146808
- Testing
- Adefovir dipivoxil and hepatitis B vaccination
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Hepatitis A, Viral Hepatitis Vaccines
Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico
This study will assess the seroprevalence of hepatitis A virus (HAV), hepatitis B virus (HBV) and Bordetella pertussis (B. pertussis) in adolescents and young adults in Mexico.
- Trial name
- NCT02112890
- Testing
- Data collection
- Where
- Mexico
- Volunteers
- 1,603 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B Virus Infection
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
To describe the immunogenicity and safety of modified process hepatitis B vaccine administered to renal predialysis and dialysis patients
- Trial name
- NCT00440297
- Testing
- Comparator: modified process hepatitis B vaccine, Comparator: ENGERIX-B™
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis A
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi.
- Trial name
- NCT00197249
- Testing
- Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Hepatitis B Challenge Dose in Adults (V232-059-10)
The purpose of this trial is to describe the Seroprotection Rate (SPR) at least 2 years following completion of a primary series with a hepatitis B vaccine (Base Study V232-059, NCT00440531) and 1 month following a challenge dose…
- Trial name
- NCT01251276
- Testing
- Modified Process Hepatitis B Vaccine
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
The purpose of this study is to demonstrate the durability of protection against hepatitis B virus (HBV) infection approximately 8-9 years after vaccination with Vaxelis®.
- Trial name
- NCT04490499
- Testing
- HBVAXPRO™
- Where
- 10 sites in Finland
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B Virus
Mutations of the Pre-core Region of Hepatite B Virus (HBV)
Hepatitis B virus (HBV) infection constitutes a major public health threat worldwide. A total of 92 patients with HBeAg-negative chronic hepatitis B infection were recruited at Amiens University Hospital.
- Trial name
- HEPATITEB (NCT03625258)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hepatitis B, Hepatitis A
Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine
To evaluate the persistence of immune response 5 years and 6 years after the first vaccine dose.
- Trial name
- NCT00197171
- Testing
- Combined Hepatitis A and B vaccine
- Where
- 2 sites in Australia
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24.
- Trial name
- OCTOPUS-1 (NCT05275023)
- Testing
- JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil
- Where
- 26 sites in Canada, Czechia and 6 more
- Volunteers
- 37 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B, Chronic
Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
The Safety, Tolerability, Pharmacokinetics and antiviral activity Study of Anti hepatitis B virus treatment drug Freethiadine in Healthy subjects and in patients with chronic hepatitis B
- Trial name
- NCT05391360
- Testing
- Freethiadine tablets(part I), Freethiadine tablets (part II), entecavir tablets
- Where
- 2 sites in China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis B
Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
The goals of therapy against chronic hepatitis B are to decrease the morbidity and mortality related to chronic HBV infection. Currently available antiviral therapy can suppress viral replication but only a small proportion…
- Trial name
- APOSTLE (NCT03312023)
- Testing
- Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Chronic Hepatitis B
Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B
The purpose of the study is to investigate the safety and the antiviral activity of ascending multiple oral doses of LB80380 for 12 weeks in adults with lamivudine-refractory chronic hepatitis B infection.
- Trial name
- NCT00895596
- Testing
- LB80380
- Where
- 4 sites in China, South Korea
- Volunteers
- 65 people
- Sponsor
- LG Life Sciences
Hepatocellular Carcinoma, Hepatitis B
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
This is a Phase II study in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B, Hepatitis C
- Trial name
- OUTREACH2 (NCT04710641)
- Testing
- MTL-CEBPA, Sorafenib
- Where
- 2 sites in United States, Singapore
- Volunteers
- 8 people
- Sponsor
- Mina Alpha Limited
Hepatitis D, Chronic, Hepatitis B, Chronic
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
The objective of this study is to determine the effectiveness of peginterferon alfa-2b 1.5 mcg/kg/week administered for 52 weeks (wk) in previously untreated participants coinfected with hepatitis virus B and D.
- Trial name
- NCT00686790
- Testing
- Peginterferon alfa-2b (PegIntron, SCH 54031)
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)
To assess the safety and immunogenicity of a booster dose of hepatitis B vaccine in children who have received a 3-dose primary series of either RECOMBIVAX HB or ENGERIX-B.
- Trial name
- NCT00393523
- Testing
- Comparator: Modified Process Hepatitis B Vaccine, Comparator: Comparator: ENGERIX-B
- Volunteers
- 1,478 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B
The purpose of the study is to compare the safety, reactogenicity and immunogenicity of different formulations of adjuvanted recombinant hepatitis B vaccine to that of Engerix™-B when administered at 0, 2 months with a booster at…
- Trial name
- NCT00698087
- Testing
- MPL-Adjuvanted recombinant hepatitis B vaccine, Engerix™-B
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Hepatitis B
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in…
- Conditions
- HIV Infections, Hepatitis B, Measles, Pneumococcal Infections
- Trial name
- NCT00013871
- Testing
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent)
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
This 3 arm study will assess the efficacy and safety of PEGASYS + entecavir combination therapy in treatment-naive patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT00614471
- Testing
- Entecavir, peginterferon alfa-2a [Pegasys]
- Where
- 8 sites in China, Hong Kong
- Volunteers
- 219 people
- Sponsor
- Hoffmann-La Roche
Diphtheria, Tetanus
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
To demonstrate that DTaP-IPV-HB-PRP~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00313911
- Testing
- DTaP-IPV-HB-PRP~T, Tritanrix-HepB/Hib
- Where
- 2 sites in Mexico, Peru
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B
Since a proportion of patients with Acute Viral Hepatitis-B develop severe hepatitis and fulminant hepatic failure, it is logical to believe that a rapid reduction in the HBV DNA levels by using antiviral agents could result in a…
- Trial name
- NCT00380614
- Testing
- Lamivudine
- Where
- India
- Sponsor
- Maulana Azad Medical College
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.